DOI: 10.1093/hropen/hoag016 Funding: Novo Nordisk Foundation, AP Moller Foundation, NordForsk, Villum Foundation, Independent Research Fund Denmark and Centre for Childhood Health Never miss a breakthrough: Join the SciTechDaily newsletter
Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis
It is a first-in-class medication that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, making it a powerful tool for managing diabetes
Lower doses may produce more subtle metabolic improvements, while higher doses tend to produce more dramatic changes across all measured parameters
Lizzo The American rapper has never shied away from embracing her body, becoming an icon for plus-size women worldwide
Evidence-based complementary and alternative medicine: eCAM